The prerequisite for a successful clinical use of autologous adipose-tissue-derived cells is the highest possible regenerative potential of the applied cell population, the stromal vascular fraction (SVF). Current isolation methods depend on high enzyme concentration, lysis buffer, long incubation steps and mechanical stress, resulting in single cell dissociation. The aim of the study was to limit cell manipulation and obtain a derivative comprising therapeutic cells (microtissue-SVF) without dissociation from their natural extracellular matrix, by employing a gentle good manufacturing practice (GMP)-grade isolation. The microtissue-SVF yielded larger numbers of viable cells as compared to the improved standard-SVF, both with low enzyme concentration and minimal dead cell content. It comprised stromal tissue compounds (collagen, glycosaminoglycans, fibroblasts), capillaries and vessel structures (CD31 + , smooth muscle actin + ). A broad range of cell types was identified by surface-marker characterisation, including mesenchymal, haematopoietic, pericytic, blood and lymphatic vascular and epithelial cells. Subpopulations such as supra-adventitial adipose-derived stromal/stem cells and endothelial progenitor cells were significantly more abundant in the microtissue-SVF, corroborated by significantly higher potency for angiogenic tube-like structure formation in vitro. The microtissue-SVF showed the characteristic phenotype and tri-lineage mesenchymal differentiation potential in vitro and an immunomodulatory and pro-angiogenic secretome. In vivo implantation of the microtissue-SVF combined with fat demonstrated successful graft integration in nude mice. The present study demonstrated a fast and gentle isolation by minor manipulation of liposuction material, achieving a therapeutically relevant cell population with high vascularisation potential and immunomodulatory properties still embedded in a fraction of its original matrix.
Introduction
Adipose-tissue-derived cells are successfully applied for the reconstruction and regeneration of damaged or diseased tissues where common therapies fail (Pak et al., 2018) . Their high regenerative potential is underlined by several clinical trials. More preclinical studies have progressed into clinical trials, www.ecmjournal.org S Nürnberger et al. Microtissue stromal vascular fraction with mesenchymal stromal/stem cells (MSCs) derived from adipose tissue, than from other sources, e.g. the bone marrow (Macrin et al., 2017) . The adipose tissue is abundantly available as an autologous cell source in most patients and provides easily obtainable regenerative cells in large amounts (Bacakova et al., 2018) . The isolated cell population, the stromal vascular fraction (SVF), contains a variety of stem, progenitor and mature cell types from haematopoietic, vascular and mesenchymal origin, such as lymphocytes, monocytes/macrophages, endothelial cells, pericytes, smooth muscle cells, fibroblasts and adipose-derived stromal/stem cells (ASCs) among others (Bourin et al., 2013; Zimmerlin et al., 2010) . ASCs can be selected as one of the adherent cell fractions, by cultivating the SVF on tissue culture plastic (Bourin et al., 2013) . They are characterised by their self-renewal potency and ability to give rise to at least adipocytic, osteocytic, chondrocytic and myocytic lineages (De Francesco et al., 2015; Gimble and Guilak, 2003a; Gimble and Guilak, 2003b; Zuk et al., 2002; Zuk et al., 2001) . ASCs in culture express some common mesenchymal stromal/stem cell markers including CD90, CD73, CD105 and CD44 and remain negative for CD45 and CD31 (Bourin et al., 2013) . During regeneration, they act as immunomodulators and can migrate to damaged areas of the body, where they secrete factors facilitating tissue repair (Bateman et al., 2018) . ASCs have regenerative potential in vitro, in animal models and in clinical studies for soft tissue reconstruction, bone and cartilage regeneration, treatment of immune diseases, cardiovascular diseases, gastrointestinal diseases, neurological diseases and diabetes, with variable success (Bateman et al., 2018; .
In recent years, there has been a shift towards using the total SVF cell population, following the concept of an intraoperative procedure bringing autologous cells back into the patient without further processing. In terms of cell-assisted lipotransfer (CAL), the addition of the SVF is successfully established in fat grafting, enhancing long-term graft stability (Gentile et al., 2012; Jiang et al., 2015) . With its potential for immunomodulation and angiogenesis, the SVF recruits vessels and induces a local regulatory, proregenerative immune cell phenotype (reviewed by Stivers et al., 2017) . Providing a clinical grade product is a critical requirement for ASC or SVF application. In contrast to the SVF, ASCs depend on in vitro expansion, which is associated with challenges such as possible cell transformation risks or stemness loss (Jiang et al., 2017; McIntosh K., 2006; Pan et al., 2014; Safwani et al., 2013) . Moreover, using the SVF during a surgical procedure in an autologous and homologous way is not considered an advanced therapy medicinal product (ATMP) (European Medicines Agency, 2012) . Still, the multiple steps of collagenase and erythrocyte lysis buffer incubation, as well as centrifugation and filtration can negatively impact on cell efficacy (Hagman et al., 2012) . Hence, there is an unmet need for a gentle isolation method providing regenerative cell populations protected by their natural environment and fulfilling all the regulatory requirements of a minimally manipulated cellular product.
The present study described a fast and particularly gentle method of SVF isolation by minor manipulation of liposuction material, achieving an SVF cell population, still embedded in a fraction of its original matrix. The microtissue-SVF was isolated from the adipose tissue with a good manufacturing practice (GMP)-certified collagenase under sterile and mild conditions and compared to the standard-SVF, both isolated with low collagenase concentration. The freshly isolated microtissue-SVF was thoroughly characterised with regards to vitality, matrix composition, cell identity and functionality. This was achieved by analysing tissue morphology, cellular composition, surface marker profile, adipogenic, osteogenic, chondrogenic and vasculogenic potential, regenerative secretome protein profile and support of graft integration after intramuscular injection in nude mice. Since adipose tissue consists of various extracellular matrix (ECM) components, together with a variety of therapeutic cells (Liu et al., 2011) , the working hypothesis was that adipose-derived microtissue-SVF, comprising therapeutic cells without dissociation from the adipose tissue ECM, might represent an optimised product for tissue repair.
Materials and Methods

Liposuction
The collection of human adipose tissue was approved by the local ethical board (application/approval number 200, 12.05.2005 and 19.05.2014 ) and written patient's consent. Subcutaneous adipose tissue was obtained from 25 patients [age: 39 ± 10 years; body mass index (BMI): 33.6 ± 6.7 kg/m 2 ] during routine outpatient liposuction procedures under local tumescence anaesthesia.
Standard-SVF isolation
Standard-SVF isolation was optimised to obtain the highest yield of a highly viable single-cell suspension under mild proteolytic conditions. Liposuction material was collected in a fully closed container and 100 mL liposuction material was transferred into a blood bag (Macopharma, Langen, Germany) and washed with an equal volume of phosphate buffered saline (PBS), to remove blood and tumescence solution (Table 1) . Next, for tissue digestion, PBS was replaced with 0.2 U/mL collagenase NB4 (Serva, Vienna, Austria) dissolved in 100 mL PBS containing Ca 2+ /Mg 2+ and 25 mM N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES; Sigma-Aldrich), resulting in a final collagenase concentration of 0.1 U/ mL. The blood bag was incubated at 37 °C under www.ecmjournal.org moderate shaking (180 rpm) for 1 h. The digested tissue was transferred into 50 mL tubes. After centrifugation at 1200 ×g for 7 min, the cell pellet was incubated with 100 mL erythrocyte lysis buffer for 5 min at 37 °C, to eliminate red blood cells. The supernatant was aspirated after centrifugation for 5 min at 500 ×g. The pellet was washed with PBS and filtered through a 100 µm cell strainer (Greiner). After another centrifugation step at 500 ×g for 5 min, the supernatant was removed. The isolated standard-SVF was resuspended in endothelial growth medium 2 (EGM-2; Lonza) and used for further analyses.
Microtissue-SVF isolation
For microtissue-SVF isolation, liposuction material was collected in a fully closed container and 100 mL were transferred into a blood bag and washed with an equal volume of PBS to remove blood and tumescence solution (Table 1) . Next, for tissue digestion, PBS was replaced with 0.2 U/mL collagenase NB6 (Serva) dissolved in 100 mL PBS containing Ca 2+ /Mg 2+ and 25 mM HEPES, resulting in a final collagenase concentration of 0.1 U/mL. The blood bag was incubated at 37 °C under moderate shaking (180 rpm) for 1 h. The digested tissue was transferred into 50 mL tubes. After centrifugation at 1200 ×g for 7 min, the cell pellet was washed with PBS. After another centrifugation step at 300 ×g for 5 min, the microtissue-SVF was resuspended in EGM-2 and used for further analyses.
Standard-SVF and microtissue-SVF cultivation
To analyse the differentiation potential, the isolated standard-SVF and microtissue-SVF were cultured for 1 week in EGM-2 at 37 °C, 5 % CO 2 and 95 % air humidity, allowing the adherent cell fraction, including ASCs, to outgrow as an adherent monolayer on tissue culture plastic. The cells were cultured to a sub-confluent state and detached with 1× trypsin/ ethylenediaminetetraacetic acid (EDTA, Lonza) at 37 °C. Medium was changed every 3-4 d.
Cell yield and viability quantification
To visualise cell vitality in pure fat (liposuction material), isolated microtissue-SVF and standard-SVF, calcein AM (ThermoFisher Scientific) and ethidium homodimer 1 (EthD-1; Sigma-Aldrich) were used. Pure fat and the isolated microtissue-SVF were placed into a 6-well plate, while the standard-SVF was pipetted into 15 mL tubes for centrifugation after each step. All 3 conditions were washed with PBS + 10 % foetal calf serum (FCS; PAA Laboratories GmbH, Pasching, Austria) and incubated at room temperature for 10 min in the dark with the staining solution containing calcein AM (2 µg/mL) and EthD-1 (1.4 µg/mL) dissolved in PBS + 10 % FCS. Next, all three conditions were washed with PBS + 10 % FCS, transferred on to microscope slides and covered with cover slips. Fluorescence and brightfield/phase lens 1 (Ph1) images were acquired using a fluorescence microscope (Axiovert 200; Zeiss). For quantification of cell yield and viability after standard-SVF and microtissue-SVF isolation, cells were stained with 4',6-diamidino-2-phenylindole (DAPI) and analysed using a cell counter (NucleoCounter ® NC-200™; ChemoMetec, Allerod, Denmark) with integrated fluorescence microscope following the "Viability and Cell Count -Aggregated Cells Assay" protocol. Each sample was transferred into a Via1-Cassette™ (ChemoMetec) coated with DAPI and two measurements were performed: one with cell lysis solution, to stain all cell nuclei in the sample, and one without lysis solution, to stain only non-viable cells.
Cellular adenosine triphosphate (ATP)
To determine cell vitality, the cellular ATP concentration, was measured using the CellTiterGlo ® Luminescent Cell Viability Assay (Promega) according to the manufacturer's instructions. The luminescent signal was detected with an Infinite ® M200 Multimode Microplate Reader (Tecan, Grödig, Austria) at an exposure time of 2 s and analysed using an ATP standard curve. 
Flow cytometry analysis
Freshly isolated SVF after standard-SVF or microtissue-SVF isolation were characterised using antibodies against a number of antigens (Table 2a) . Specific subpopulations were analysed through combination of the antibodies CD31, CD34, CD45-V500 Horizon (BD Biosciences), CD90, CD146, SSEA3, CD105, LYVE-1 and podoplanin (Table 2b ). For staining, 5 × 10 5 cells in 50 µL PBS with 1 % FCS were incubated with 5 µL primary labelled antibodies at room temperature for 15 min in the dark. Cells were washed with 1.5 mL Cell Wash™ (BD Biosciences, Schwechat, Austria) and centrifuged for 5 min at 400 ×g. The supernatant was discarded and the cell pellet resuspended in 300 µL 1× Cell Fix™ (BD Biosciences; diluted 1 : 10 with Aqua Dest, Fresenius Kabi, Linz, Austria). For staining with the intracellular marker α-SMA, cells were first resuspended in 1× Cell Fix™ and Cell Wash™ containing 0.1 % Triton X-100 was used for all washing steps. 3 µL of α-SMA were added, cells were incubated at room temperature for 30 min in the dark and, after centrifugation for 5 min at 400 ×g, resuspended in PBS. All samples were analysed using a flow cytometer (FACSCanto; BD Biosciences).
Histological staining
In vitro and in vivo standard histological samples were fixed with 4 % neutral buffered formalin for 24 h and rinsed in PBS. Then, samples were dehydrated in graded series of ethanol, followed by xylol and embedding in paraffin. 3-4 µm-thick sections were cut using a rotary microtome (HM355S Microm; ThermoFisher Scientific) and deparaffinised for either histochemical or immunohistochemical analysis. Microtissue-SVF and pellets were histochemically stained with alcian blue to display the glycosaminoglycan content. Subcutaneously implanted fat and microtissue-SVF-samples were stained with haematoxylin and eosin (H&E) for overview of integration into the surrounding skin and muscles. Microtissue-SVF and pellets were immunohistochemically stained for ECM components (collagen type I, type II and type III) and cell markers [fibroblast (clone TE-7), endothelial cells (CD31) and pericytes (SMA)]. Deparaffinised sections were prepared by blocking the endogenous peroxides and alkaline phosphatase with BIOXALL ® (Vector Labs); antibody retrieval was performed with steaming at pH 9.0 (Tris-EDTA buffer) for SMA and pH 6 (citrate buffer) for collagen type I and CD31, pepsin for collagen type II, proteinase K for collagen type III, fibroblasts and CD31. Then, antibodies were incubated for 1 h: collagen type I (Abcam) 2 µg/mL, collagen type II (ThermoFisher Scientific) 2 µg/mL, collagen type III (Abcam) 5 µg/ mL, fibroblasts (Millipore) 0.125 µg/mL, CD31 (DAKO) 10.25 µg/mL, SMA (Sigma-Aldrich) 0.4-1.2 µg/mL. The polymer-labelled system Bright vision poly HRP (Immunologic, Duiven, the Netherlands) was used as secondary antibody and incubated for 30 min. Visualisation was done with the peroxidase substrate NovaRED™ (Vector Laboratories) and counterstaining with haematoxylin. A special fixation protocol was further used to display the fat content in pure fat samples, microtissue-SVF and standard-SVF. After primary fixation with formalin and rinsing, the samples were fixed for 4 h with 2 % osmium tetroxide (OsO 4 ) to preserve and visualise lipids. After subsequent rinsing, the samples were processed as the standard histological sections and stained with H&E. Images were acquired with a light microscope (Nikon E800; Nikon).
Immunofluorescence staining
To visualise CD34 + /CD90 + cells as indicator for ASCs presence (De Francesco et al., 2009) , pure fat and isolated microtissue-SVF were placed into a 12-well plate. Both were washed with PBS, then blocked at room temperature for 2 h with a solution containing PBS, 0.2 % bovine serum albumin (BSA; BD Biosciences) and 0.1 % gelatine from cold-waterfish skin (Sigma-Aldrich). The same solution was used during the incubation with the antibody and for the washing steps, if not indicated differently. The primary antibodies CD34 and CD90 (both 1 µg/ mL; Novus/Bio-Techne Ltd., Abingdon, UK) were applied overnight at 4 °C. On the next day, both conditions were washed and incubated for 4 h at room temperature in the dark with the secondary antibodies goat anti-mouse Rhodamine Red™-X and donkey anti-rabbit Alexa Fluor 488 (both 1 µg/mL; Invitrogen). Nuclear counterstaining was performed with DAPI (0.38 ng/mL; Invitrogen) at room temperature for 10 min in the dark. The samples were washed with PBS and mounted on microscope slides using the Prolong Antifade kit (Molecular Probes). Images were acquired using a confocal microscope (Nikon C2, Nikon).
Enzyme-linked immunosorbent assay (ELISA)
To analyse the secretion of human indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2), the supernatant of freshly isolated standard-SVF and microtissue-SVF was cultivated for 24 h in sterile-filtered Dulbecco's modified Eagle's medium (DMEM)-low glucose (Lonza) containing 10 % FCS and 2 mM L-glutamine (PAA Laboratories GmbH). The supernatant was collected and stored at − 80 °C until analysis. An IDO DuoSet ELISA Development System kit (R&D Systems) and a Prostaglandin E2 ELISA Kit (Abcam) were used according to the manufacturer's instructions. Absorbance was measured using an Infinite ® M200 Multimode Microplate Reader (Tecan) and correlated to a standard curve.
Trophic factor release
For trophic factor release analysis of freshly isolated standard-SVF and microtissue-SVF, 5 × 10 5 cells were seeded in a T-25 flask in 2.5 mL EGM-2 medium. Cells were allowed to adhere for 2 h and, subsequently, www.ecmjournal.org Table 2a . List of antibodies against which antigens were obtained. Freshly isolated SVF after standard-SVF or microtissue-SVF isolation were characterised using antibodies against these antigens. Details of suppliers are included. α-SMA: alpha-smooth muscle actin; APC: allophycocyanin; CD: cluster of differentiation; PerCP: peridinin chlorophyll protein complex; FITC: fluorescein-isothiocyanate; PE: phycoerythrin; LYVE-1: lymphatic vessel endothelial receptor 1; SSEA3: stage-specific embryonic antigen 3. EGM-2 media was changed to serum-free media (DMEM-low glucose with 2 mM L-glutamine). To include also non-adherent suspension cells, cells were collected, centrifuged and returned to the flask. 24 h after seeding, the supernatant was collected and stored at − 80 °C until analysis. A customised array (RayBio, Norcross, GA, USA) was used for the trophic factor release analysis and performed according to the manufacturer's instructions. Signals were detected by enhanced chemiluminescence and recorded on an X-ray film. Signals were densitometrically quantified using ImageJ (NIH).
Vascularisation induction and detection
For determination of the vascularisation potential of standard-SVF and microtissue-SVF, a fibrin clot culture was performed . 4 × 10 5 SVF cells after standard-SVF and microtissue-SVF isolation were mixed with fibrinogen (2.5 mg/ mL; Baxter) and thrombin (0.2 U/mL; Baxter) for clot formation and pipetted on coverslips in 12-well plates. Clots were polymerised at 37 °C for 30 min and cultured for 2 weeks in EGM-2 containing aprotinin (100 KIU/mL; Baxter). Medium was changed every 3-4 d. After cultivation, clots were fixed with 4 % paraformaldehyde (PFA), washed with PBS and incubated for 12 h in the dark with a FITC-conjugated monoclonal mouse anti-human CD31 antibody (1 : 50 dilution in PBS/1 % BSA). Clots were again washed with PBS, then nuclear counterstaining was performed with DAPI (0.38 ng/mL in PBS/1 % BSA) for 10 min at room temperature in the dark. For images in higher magnification, clots were incubated for 12 h in the dark with an Alexa-Fluor ® -647-conjugated monoclonal mouse anti-human CD31 antibody (BD Biosciences; 1 : 100 dilution in PBS/1 % BSA). Images were acquired using a fluorescence microscope (Axiovert 200 or Observer Z.1 for higher magnification). Number of vascular tubes per picture was counted.
In vivo experiments
An animal experiment permit was issued by the municipal government of Vienna and all experimental methods were consistent with the Guide for the Care and Use of Laboratory Animals of the US National Research Council (2011). For analysis of graft integration, pure fat and fat enriched with microtissue-SVF (2.5 × 10 5 cells/50 µL fat) in a 9 : 1 ratio were injected intramuscularly into nude mice. A total of 16 NMRI nude mice (Charles River) weighting 22-27 g underwent surgery. After induction of anaesthesia by isoflurane (AbbVie), 50 µL test samples were injected transcutaneously into the musculus quadriceps femoris hindlimbs in a randomised fashion. Either microtissue-SVF or a combination of fat and microtissue-SVF were applied in 6 replicates, while the remaining untreated hindlimbs served as an empty control. The implants were well tolerated and no adverse effects were observed. Analgesia was provided orally by 1 mg/kg meloxicam (Boehringer Ingelheim) prior to surgery and for up to 3 d post-surgery. After 28 d, the animals were euthanised through cervical dislocation under isoflurane inhalation anaesthesia and samples were harvested by resecting the implantation region with the skin and subcutaneous tissue. The samples were fixated and histologically processed as described above in the histological staining section.
Adipogenic differentiation and detection
For adipogenic differentiation, cells derived from microtissue-SVF after 1 week in culture were seeded at a density of 7.4 × 10 3 /cm 2 in EGM-2 and incubated overnight. On the next day, medium was changed to adipogenic differentiation medium (DMEM)-high glucose (Lonza) containing 10 % FCS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin (P/S; Lonza), 1 µM dexamethasone (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; SigmaAldrich), 10 µg/mL insulin (Sigma-Aldrich) and 100 µM indomethacin (Sigma-Aldrich) or control medium consisting of DMEM : F12/L-glutamine (Lonza) with 10 % FCS and 100 U/mL P/S. Medium was changed every 3-4 d. After 1, 2, 3 and 7 d, adipogenic differentiation was analysed with oil red O staining and quantification through RT-PCR of the specific markers, peroxisome proliferator-activated receptor gamma (PPARγ), fatty acid-binding protein 4 (FABP4) and leptin (LEP). For oil red O staining of lipid droplets, cells were fixed for 1 h with 4 % formaldehyde. After washing with Aqua Dest, the cells were rinsed with 70 % ethanol for 2 min and stained for 5-15 min with oil red O solution (SigmaAldrich). Then, the cells were washed with Aqua Dest, counterstained for 1-3 min with haematoxylin solution and washed with tap water. Images were acquired using a light microscope (Axiovert 200).
Osteogenic differentiation and detection
For osteogenic differentiation, cells derived from microtissue-SVF after 1 week in culture were seeded at a density of 1.1 × 10 3 /cm 2 in EGM-2 and incubated overnight. On the next day, medium was changed to osteogenic differentiation medium DMEM-low glucose containing 10 % FCS, 2 mM L-glutamine, 100 U/mL P/S, 10 nM dexamethasone, 150 µM ascorbat-2-phosphate (Sigma-Aldrich), 10 mM β-glycerophosphate (StemCell Technologies, Cologne, Germany) and 10 nM dihydroxy-vitamin D3 (Sigma-Aldrich) or control medium consisting of DMEM : F12/L-glutamine with 10 % FCS and 100 U/ mL P/S. Medium was changed every 3-4 d. After 21 d, osteogenic differentiation was analysed with alizarin red staining and quantification through RT-PCR of the specific markers alkaline phosphatase (ALPL), osteocalcin (BGLAP) and osteopontin (SPP1). For alizarin red staining of calcified structures, cells were fixed for 1 h with 70 % ethanol at − 20 °C and stained with alizarin red solution (Merck) for 15 min. Images were acquired using a light microscope (Axiovert 200). www.ecmjournal.org
Chondrogenic differentiation and detection
For chondrogenic differentiation in 3D micromass pellet cultures, 3 × 10 5 cells derived from microtissue-SVF after 1 week in culture were centrifuged in chondrogenic differentiation medium [hMSC Chondro BulletKit (Lonza), 10 ng/mL BMP-6 (R&D) and 10 ng/mL TGF-ß3 (Lonza)] in screw-cap micro tubes. The tubes were placed in an incubator at 37 °C, 5 % CO 2 and 95 % humidity with slightly open cap to allow for gas exchange. After 2 d, the pellets were transferred to 96-well U-bottom plates (Greiner) with fresh medium. Medium was changed every 2-3 d. After 35 d of differentiation, chondrogenic differentiation was analysed with alcian blue and collagen type II staining as well as quantification through RT-PCR for the specific markers collagen type II alpha 1 (COL2A1) and aggrecan (AGC1) versus collagen type I alpha 1 (COL1A1) and versican (CSPG2). Histological samples were processed as described above in the histological staining section.
Quantitative RT-PCR
Samples for qRT-PCR were collected at distinct time points as indicated in the differentiation paragraphs and lysed or homogenised in TriReagent (SigmaAldrich). Extraction was facilitated by repeated pipetting of the cells or pellets. For total RNA isolation, the samples were centrifuged for 10 min at 4 °C and the supernatant was transferred into a fresh tube. For phase separation, 0.1 mL of 1-bromo-3-chloropropane (BCP; Sigma-Aldrich) was added and samples shaken vigorously, incubated for 10 min and centrifuged for 10 min at 4 °C. The aqueous phase was transferred into a fresh tube and precipitated with isopropanol for 30 min at − 20 °C. After centrifugation for 30 min at 4 °C, the RNA pellet was washed with 75 % ethanol, vortexed and centrifuged for 5 min at 4 °C. Finally, RNA pellets were air-dried before dissolving them in nuclease-free water (Promega). Samples were stored at − 80 °C until use. RNA content and integrity were assessed using an Agilent 2100 Bioanalyzer with the RNA 6000 Nano Chips Kit (no. 5065-4476, Agilent Technologies). Isolated RNA was retrotranscribed to cDNA according to the High Capacity cDNA Archive Kit protocol (Applied Biosystems). Quantification of specific cDNAs was conducted in triplicate, using a LightCycler W 480 (Roche) and TaqMan™ gene expression assay (Applied Biosystems) for PPARγ (Hs00234592_m1), FABP4 (Hs00609791_m1), LEP (Cf02692890_m1), ALPL (Hs00758162_m1), BGLAP (Hs01587813_g1), SPP1 (Hs00167093_m1), CSPG2 (Hs00171642_m1), COL1A1 (Hs00164004_m1), COL2A1 (Hs00264051_ m1) and AGC1 (Hs0015936_m1). The PCR was programmed as follows: initial denaturation at 95 °C for 10 min, followed by 95 °C for 10 s, 60 °C for 45 s, cycled 50 times. Cooling to 40 °C was held for 30 s. Slope speed was 20 °C/s. Standard curves were prepared for quantification and expression values were normalised to the housekeeping gene, hypoxanthine-guanine phosphoribosyl transferase (HPRT). The efficiency-corrected quantification was performed automatically, using the LightCycler 480 Relative Quantification Software (Roche).
Statistical analysis
Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using PRISM6 (GraphPad), parametric two-tailed t-test or two-way ANOVA Tukey's post-hoc for trophic factor release analysis. p < 0.05 was considered statistically significant.
Results
The optimised standard-SVF isolation protocol with low collagenase concentration was adapted resulting in SVF cells being protected within their natural environment, hence providing a microtissue devoid of fat components and highly enriched in SVF cells.
Microtissue-SVF isolation increased cell yield and viability
The macroscopic and microscopic appearance of the microtissue-SVF was characterised by a heterogeneous and partially fibrous matrix with individually distributed cells and cell aggregates. In contrast, pure fat contained few individual cells and was dominated by lipid droplets, while the standard-SVF consisted of single cells and small cell aggregates ( Fig. 1a; phase contrast, live/dead staining, OsO 4 fixation). Staining of live (calcein AM) versus dead (EthD-1) cells revealed a small and moderate number of dead cells in pure fat and standard-SVF, respectively, but almost none in the microtissue-SVF. The appearance of the native fat tissue was dominated by living cells with adipocyte morphology. In the microtissue-SVF, the living cells mainly resided within the ECM areas, which suggested a protective role of the microtissue. Automated quantification of the viable versus dead cells in microtissue-SVF versus standard-SVF isolation supported the morphological data. Microtissue-SVF had a 10 % increased viability as compared to standard-SVF isolation (Fig. 1b) . Not only the viability was increased in the microtissue-SVF but also the total cell yield, which was significantly higher (1.8-fold) as compared to standard-SVF isolation (Fig. 1b) . ATP concentration as an indicator for cellular fitness and energy production was at similarly high levels in both SVF isolates.
The microtissue-SVF maintained the heterogeneous SVF character According to the guidelines of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) (Bourin et al., 2013) , the isolated standard-SVF and microtissue-SVF were characterised for the distinct surface marker profile by flow cytometric analysis. Table 3 . Identification and quantification of surface marker in standard-SVF and microtissue-SVF with flow cytometry analysis. The standard-SVF and microtissue-SVF revealed all SVF-specific immunophenotype marker analysed by flow cytometry according to the guidelines of the IFATS and ISCT. Additionally, further marker for distinct stem and progenitor cell types could be detected (n = 4 for microtissue-SVF and n = 3 for standard-SVF). Data are presented as mean ± SD. Stro-1 Mesenchymal stromal 6 ± 1 8 ± 5
Marker Positive cells (%)
Microtissue-SVF structure
Comparison between microtissue-SVF, standard-SVF and pure fat revealed that the most obvious feature of the microtissue-SVF was the large amount of ECM with a simultaneous lack of lipid, represented by few residual droplets only (Fig.  1) . Also, macroscopically, the appearance of the microtissue-SVF was dominated by its matrix that gave the material a translucent to opaque mucous appearance containing fibrous elements (Fig. 2a) .
To characterise this matrix and its structural relation with the cells, detailed morphological analyses were performed. Matrix-specific histochemical and immunohistochemical stainings identified mucopolysaccharides (alcian blue) and collagen type I (antibody labelling) as the main ECM components (Fig. 2b,c) . Mucopolysaccharides appeared as homogenous areas with few cells that were mainly individually distributed. Collagen type I formed fibrous strands within the mucous matrix or areas of fine fibrillary networks. The latter were co-localised with collagen type III and areas of high cellularity (Fig. 2d) . Cells forming lumina and tube-like structures were identified as endothelial cells (CD31 + ), either appearing alone as capillaries or surrounded by pericytes (SMA + ) (Fig. 2f) . Within these vessel and cell aggregates, also fibroblasts (clone TE-7 + ) were identified (Fig. 2e) . The areas with high cellularity, rich in collagen matrix, and the areas with low cellularity, rich in mucopolysaccharides, had an extension of few hundreds µm and were spread-out evenly throughout the microtissue-SVF (Fig. 2b-f 
Microtissue-SVF isolation increased the percentage of specific subpopulations
As the cell yield was increased after microtissue-SVF isolation, whether this increase might correlate with the enrichment of specific subpopulations within the heterogeneous SVF was examined. Interestingly, EPCs (1.8-fold) and SA-ASCs (1.7-fold) were significantly increased by microtissue-SVF isolation as compared to standard-SVF isolation (Fig. 4) . The relative number of pericyte-like cells was similar after standard-SVF and microtissue-SVF isolation.
The microtissue-SVF showed enhanced release of PGE2 As trophic factors are highly relevant for tissue repair (Fu et al., 2017) , the secretion of pro-regenerative factors (e.g. angiogenic and immunomodulatory) was explored in supernatants conditioned for 24 h with freshly isolated standard-SVF and microtissue-SVF. Substantial levels of IDO and PGE2, two mediators of immunomodulation, were detected in both SVF variants. IDO concentration was increased in microtissue-SVF (2.4-fold) as compared to standard-SVF supernatant, although not reaching significance (Fig. 5) . However, there was a highly significant increase in PGE2 (15-fold) in microtissue-SVF as compared to standard-SVF supernatant. All analysed factors were expressed in the supernatant of both SVFs (Fig. 5) at similar protein levels in the standard-SVF and microtissue-SVF, as measured by a customised array microarray (RayBio). There was a slight but not significantly enhanced release of interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2 and epidermal growth factor (EGF) after microtissue-SVF isolation.
The microtissue-SVF displayed a high vascularisation potential
Efficient vascularisation is a key element in regeneration and for successful graft integration and survival in tissue engineering (Eto et al., 2012) . Therefore, standard-SVF and microtissue-SVF were characterised in 3D fibrin matrices for their potential to form tube-like structures, an in vitro indicator for angiogenesis (Rohringer et al., 2014) . After 2 weeks, microtissue-SVF isolation showed a more pronounced vascular network formation of CD31 + cells as compared to standard-SVF isolation (Fig. 6a) . A higher magnification demonstrated a branching point in the microtissue-SVF. Quantitative analysis revealed a significantly larger number of tubes in the microtissue-SVF group (2.9-fold) (Fig. 6b) , suggesting an improved vascularisation potential.
The microtissue-SVF was successfully integrated into the surrounding tissue after intramuscular injection
One typical clinical application is the use of SVF together with fat grafting material to prolong graft survival, improve vascularisation and integration of transplanted grafts in the surrounding tissue (Yoshimura et al., 2008) . Therefore, pure fat and fat enriched with microtissue-SVF were injected intramuscularly into nude mice. Both grafts integrated after 14 d, whereas microtissue-SVF cotransplantation resulted in high cellularity in the adipose tissue and a high degree of vascularisation (Fig. 7) .
The microtissue-SVF showed a trilineage differentiation potential
The microtissue-SVF was analysed for its in vitro differentiation potential using standard differentiation cultures, analysed by quantitative RT-PCR and histological staining. Upon adipogenic Muse cell 7 ± 3 7 ± 1 www.ecmjournal.org induction, the adipogenic markers PPARγ, FABP4 and LEP were significantly upregulated after only 1 d (Fig. 8a ). The staining with oil red O demonstrated that lipid droplet formation started after only 2 d and was pronounced after 7 d of differentiation (Fig.  8b) . These results indicated the excellent adipogenic differentiation potential of the microtissue-SVF, as adipogenic differentiation is detected after 14-21 d of induction in previous studies (Priglinger et al., 2018; Priglinger et al., 2017) . Upon osteogenic induction, expression of the specific osteogenic markers ALPL, BGLAP and SPP1 was increased after 21 d, being significant for BGLAP and SPP1 (Fig. 8c) . Mineral deposition staining with alizarin red at the same time point confirmed the osteogenic differentiation of the microtissue-SVF (Fig. 8d) . Chondrogenic differentiation was analysed using 3D micromass pellet cultures. After 35 d, the general expression of matrix proteins was significantly enhanced as compared to standard-SVF (COL1A1, COL2A1 and AGC1; Fig. 8e ). The differentiation index of COL2A1/COL1A1 and AGC1/CSPG2 revealed a higher activation of cartilage specific components (Fig. 8f) . Also, the histological analysis showed a strong staining with alcian blue and collagen type II, which demonstrated the potential for chondrogenic differentiation and cartilage-like tissue formation (Fig. 8g) . These results confirmed the trilineage differentiation potential of the microtissue-SVF. Fig. 2 . Characterisation of the matrix and cellular components of the microtissue-SVF. (a) Macroscopically, the microtissue-SVF appeared as a translucent to opaque mucous material with fibrous elements. In histological sections, the matrix stained with (b) alcian blue for mucopolysaccharides in some regions, while other areas were positive for (c) collagen type I and (d) III, which were co-localised. Collagen-rich areas were highly cellular and vessels were discernible (inserts). (f) The inner wall of the vessels was positive for the endothelial marker CD31 and, in some cases, the surrounding cells were SMA + , indicating pericytes. Apart from vessels, also fibroblasts (e) were identified in the highly cellular, collagen-rich areas (n = 3). Representative images. Scale bar = 100 µm.
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Discussion
The regenerative characteristics of an intraoperative GMP-compliant fat derivative with minimally manipulated cells termed microtissue-SVF was described. Until now, there were two ways for SVF isolation, diverse non-enzymatic methods using physical forces and enzymatic methods e.g. using collagenase, both followed by a cell selection step, mostly performed by centrifugation (Oberbauer et al., 2015) . Mechanical emulsification alone leads to partial disruption of mature adipocytes and ECM components -generating homogenised adipose tissue fragments which are optimal for fat grafting -but does not generate single SVF cells (Oberbauer et al., 2015) . Differently, the enzymatic dissociation of cell-cell and cell-tissue/matrix contacts provides a single-cell suspension defined by the IFATS and ISCT as SVF (Bourin et al., 2013) . Several isolation protocols aim to optimise and standardise the SVF isolation procedure (Aronowitz et al., 2018; Raposio et al., 2017) . SVF cells dissociated from their natural microenvironment lack ECM protection from possible negative enzymatic impact (Busser et al, 2014; Seaman et al 2015) . A rough enzymatic treatment, modifying substantially cell-matrix compounds, may affect the expression of surface antigens and immune cell function (Autengruber et al., 2012; Hagman et al., 2012) . Substantial cell manipulation may impact cell therapeutic classification according to the local regulatory requirements. Since both, the current physical force and enzymatic isolation strategies, have drawbacks, there is a demand for an advanced SVF generation strategy. The described SVF-derivative delivered minimally manipulated therapeutic cells incorporated within their ECM, which served as a protective scaffold and provided the most natural environment for the cells. To demonstrate the highest possible cell quality for transplantation, the microtissue-SVF was analysed immediately after isolation. In comparison with the standard-SVF, which is a protocol already optimised by the authors with low enzyme concentration, the microtissue-SVF revealed a substantially higher cell yield, combined with high vitality and metabolic activity of the enriched cells. The percentage of dead cells was very low, suggesting that the procedure was well suited to actively remove adipocytes, while maintaining SVF cells highly viable.
Microtissue-SVF cells were supported by a gellike carrier (ECM residuals) and represented the + cells (red) were visible (nuclei stained blue). The insert showed a higher magnification of a pair of CD34 + and CD90 + cells. Some cells were double stained and appeared in yellow (arrows). In the microtissue-SVF (right), cells were aggregated on/in the matrix. Apart from the green CD34 + cells, a large proportion of cells were CD90 + (red) and some were double stained (arrow). Representative confocal images, overlay. Scale bar = 100 µm. Fig. 4 . Flow cytometry analysis of SVF subpopulations. In the microtissue-SVF, endothelial progenitor cells and supra-adventitial adiposederived stromal/stem cells were significantly enriched as compared to the standard-SVF. Pericyte-like cells had similar abundance in both types (n = 4). Data are presented as mean ± SD; * p < 0.05; ** p < 0.01. www.ecmjournal.org stromal and the vascular fraction of the adipose tissue. It comprised fragmented connective tissue matrix and vascular structures composed of endothelial cells and pericytes and other regenerative cells, such as the ASCs. ECM components directly influence cell behaviour, including adhesion, spreading, proliferation and migration (Geutjes et al., 2010; Kim et al., 2012; Prockop, 2007; Wang et al., 2013a) , suggesting a positive effect on the cells embedded in the microtissue-SVF. Qiu et al. (2018) employ decellularised fat tissue ECM as a scaffold for reseeding MSCs, resulting in improved regenerative efficacy in muscle tissue injury. Beside the typical IFATS-defined SVF-cell surface markers for mesenchymal, endothelial and haematopoietic cells (Bourin et al., 2013) , the microtissue-SVF contained a broad range of cell types including pericytic, blood and lymphatic vascular and epithelial cells. Almost all markers tended to be enhanced in the microtissue-SVF as compared to the standard-SVF. Considering the morphological appearance of the microtissue-SVF, the additional cells might derive from densely organised, collagen-and vesselrich areas of the derivative that were partially lost during the additional processing of the standard-SVF isolation. Beside surface markers, a functional criterion to define the ASCs is their trilineage differentiation potential into the mesodermal lineages (Bourin et al., 2013) . The microtissue-SVF revealed a high differentiation potential towards the adipo-, osteo-and chondrogenic lineage, which confirmed the large number of ASCs, as indicated by the phenotypic MSC marker profile. Especially, adipogenesis was surprisingly rapid and could be Fig. 5 . Trophic factor release by the standard-SVF and microtissue-SVF. Both SVF types showed a typical immunomodulatory and pro-angiogenic protein profile. Notably, the microtissue-SVFs (n = 1-2, 2-4 biological replicates) secreted more IDO as compared to the standard-SVFs (n = 1, 2-4 biological replicates) and significantly more PGE2, both anti-inflammatory factors. In general, inflammatory and anti-inflammatory factors of both SVF types showed a similar tendency, with individual marker slightly up or down regulated. Data are presented as mean ± SD; **** p < 0.0001.
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Microtissue stromal vascular fraction observed already after 2-3 d of differentiation by FABP4 and LEP RT-PCR. For a potential cell therapeutic, it is important to deliver highly regenerative cell types (Corselli et al., 2013) , which were found in the microtissue-SVF by subpopulation screening. Distinct regenerative SVF populations, such as Muse cells [a stress resistant stem cell population (Kuroda and Dezawa, 2014) ], a pericytic subset CD90 + /CD146 + (Priglinger et al., 2017) and lymphatic endothelial cells, were present in the microtissue-SVF. Kuroda et al. (2010) show that Muse cells can be obtained as a minor subset from MSCs and are able to differentiate into ectodermal, endodermal and mesodermal lineage in vivo and have the capacity to replace damaged tissue, as demonstrated for liver regeneration (Katagiri et al., 2016 
/CD31
− cells with spindleshaped morphology and adipogenic potential, located on the adventitial stromal ring of vessels. In terms of regenerative action, CD34 is an important marker in SVF-derived cells (Guo et al., 2016) . CD34 is expressed on various subpopulations of progenitor cells (Scherberich et al., 2013) and tissue-resident MSCs (Lin et al., 2012) ; however, its expression is lost during cell expansion . In the microtissue-SVF, flow cytometry double staining revealed that all CD34 + cells were also CD90 + , which was in accordance with a recent publication by Lutfi et al. (2018) .
The MSC regenerative potential does not only derive from the cells with the potential to integrate and form new tissues but also from the factors they release to impact the local cells at the defect site (Kober et al., 2016; Salgado et al., 2010) . These include immunomodulatory, angiogenic and antiapoptotic factors (Kapur and Katz, 2013) . Both, the microtissue-SVF and standard-SVF showed a typical Quantitative analysis of tube number confirmed the morphological impression with a significant increased number of tubes in the microtissue-SVF group (n = 3; 5 biological replicates) as compared to the standard-SVF group (n = 4; 6 biological replicates). Data are presented as mean ± SD; * p < 0.05. www.ecmjournal.org immunomodulatory and pro-angiogenic protein profile, reflecting MSC properties (Ward et al., 2018) . Notably, the microtissue-SVF secreted substantially higher PGE2 levels, which is a major mediator of MSC immunomodulation . Successful adipose tissue formation can be observed with decellularised adipose tissue ECM combined with ASCs after 8 weeks in rats (Wang et al., 2013b) . The regenerative macrophage-regulating interplay between MSCs and heart-tissue ECM can also be observed after decellularisation and reseeding of ECM scaffold in muscle regeneration (Qiu et al., 2018) . In contrast, the gentle isolation procedure described resulted in therapeutic cells without dissociation and denaturation from the surrounding ECM, thereby making the procedure of decellularisation and reseeding redundant and providing a gently treated microtissue, which might positively influence a balanced M1/M2 macrophage response.
In fat grafting for cosmetic or reconstructive reasons, multiple strategies aim at generating a micronised homogenous tissue, which allows transplantation of an adipose matrix depleted of mature adipocytes. These strategies lead to improved volume retention lacking cysts and necrotic tissue (Li et al., 2017 ). Similar to the described approach, the enrichment of the SVF together with matrix and microvasculature may contribute substantially to the superior quality of these grafting materials (Feng et al., 2015; van Dongen et al., 2016) . In comparison to the standard-SVF, the microtissue-SVF demonstrated a highly elevated potential to form tube-like structures in vitro, indicative of its angiogenic potential in vivo. The reason for the remarkable angiogenic potential may relate to the components of the micro vessels and capillaries (found in histology) that were preserved by the gentle isolation protocol. The interplay of vascular cells with ASCs and their secreted angiogenic factors (Rohringer et al., 2014) give rise to a faster and more efficient angiogenic process (Pill et al., 2015) . A high angiogenic potential is obligatory for successful graft integration and survival (Kakagia and Pallua, 2014; Luo et al., 2013) . Luo et al. (2015) co-implant sorted endothelial cells from SVF with a fat graft in mouse leading to a high degree of vascularisation in a dosedependent manner. This is in concordance with the presented in vivo implantation experiment, showing that co-transplantation of the microtissue-SVF with fat resulted in vascularisation of the integrated graft.
Enhanced wound healing properties are demonstrated with a fat graft termed ECM/SVF-gel, secreting high MCP-1 and angiogenic factors (Liu et al., 2011; Sun et al., 2017) , suggesting wound healing as another field of application for the microtissue-SVF. A high angiogenic potential particularity predestines the material for regeneration of large areas of vascularised tissues, such as large skin defects and bone replacement (Jacobsen et al., 2008) . SVF enhances bone formation due to its proangiogenic properties, as shown in a clinical study with natural scaffolds (Farre-Guasch et al., 2018) . The microtissue-SVF as cell-loaded, pre-vascularised matrix could serve as graft or additive to vascularise newly developing tissue and reconnect vessels to host tissue. In myocardial regeneration, apart from vascularisation, also the mode of application of therapeutic cells and factors to the site of damage has raised problems. Intracoronary and intramyocardial injection of stem cells of different sources does not lead to the expected clinical outcome (Choudhury et al., 2017; Comella et al., 2016; Gyongyosi et al., 2015; Povsic et al., 2016) and application with biomaterials has limited success in clinical trials (Frey et al., 2014; Rao et al., 2015) . As the microtissue-SVF is a cell-loaded hydrogel-like material, it might be a feasible material for application to the site of injury Fig. 7 . In vivo implantation of pure-fat-and microtissue-SVF-supported fat graft. Pure fat either alone or in combination with the microtissue-SVF were intramuscularly injected into nude mice (n = 16) and showed better integration (connective tissue formation) and higher vascularisation in the presence of the microtissue-SVF. H&E staining. Representative images. Scale bar = 100 µm.
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Microtissue stromal vascular fraction The increased immunomodulatory activity of the microtissue-SVF and the presence of regenerative cells predestine it for application in inflammatory disease with associated tissue damage. Since the microtissue-SVF further revealed a high chondrogenic differentiation potential (collagen type II and aggrecan expression and matrix deposition), it fulfils the requirements for application in osteoarthritis (OA). Previous approaches already show a therapeutic effect of either ASCs or SVF after intraarticular injection into the osteoarthritic joints (Jo et al., 2014; Pak et al., 2016a; Spasovski et al., 2017) . The microtissue-SVF could be suitable to further improve the regenerative efficiency of SVFbased methods by direct application of the matrixentrapped cells to smoothen the rough surface and provide a temporal scaffold. The ECM protects the cells from direct impact by the surrounding tissues, which might increase the chance for survival and tissue regeneration. In contrast to similar approaches with current mechanical breakdown of the ECM (Pak et al., 2016b) , the microtissue-SVF was minimally manipulated to reduce the stress on the cells (compression, shear force from preparation, pipetting and centrifugation) and to retain most possible bioactive composites. The ECM with its partially large collagen bundles provides a scaffolding effect and is especially predestined for applications such as strongly affected joints with large cartilage tissue loss.
In summary, a microtissue-SVF was developed from adipose tissue for intraoperative use by optimising an isolation protocol using GMP-grade reagents and procedures. The microtissue-SVF was rich in regenerative cells surrounded by intact vessels and endogenous ECM, creating a unique natural transplantable niche. This complex environment of ECM, SVF cells and their secretome potentially facilitates neovascularisation, immunomodulation and differentiation. The microtissue-SVF could provide a potent transplant for structural restoration of tissue defects for autologous clinical applications in regenerative medicine.
